SCHEMBL5357953

SCHEMBL5357953

O=C(NCCc1ccccc1F)C1(c2ccccc2F)CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 5/20 0.59
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
P2RX7 Q99572 1/20 0.47
CNR1 P21554 1/20 0.45
NPC1 O15118 2/20 0.44
PAX8 Q06710 1/20 0.44
KLF5 Q13887 1/20 0.44
TRPV1 Q8NER1 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.42
OPRL1 P41146 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
HIF1A Q16665 2/20 0.42
KDM4E B2RXH2 1/20 0.42
RAB9A P51151 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353363 0.88 SMN1; SMN2 (0.63) HDAC4HTTSMN1; SMN2P2RX7CNR1
SCHEMBL14516605 0.88 HDAC4 (0.52) HDAC4HTTSMN1; SMN2P2RX7CNR1
SCHEMBL5355981 0.86 SMN1; SMN2 (0.53) HDAC4HTTSMN1; SMN2P2RX7CNR1
SCHEMBL5348970 0.84 SMN1; SMN2 (0.51) HDAC4HTTSMN1; SMN2P2RX7CNR1
SCHEMBL5345980 0.84 CNR1 (0.55) HDAC4HTTSMN1; SMN2CNR1LMNA
SCHEMBL5352614 0.84 HDAC4 (0.56) HDAC4HTTSMN1; SMN2CNR1NPC1
SCHEMBL5356509 0.83 SMN1; SMN2 (0.50) HDAC4HTTSMN1; SMN2P2RX7CNR1
SCHEMBL14516606 0.82 HDAC4 (0.53) HDAC4HTTSMN1; SMN2P2RX7CNR1
SCHEMBL14491550 0.81 HDAC4 (0.56) HDAC4HTTSMN1; SMN2TRPV1LMNA
SCHEMBL14516603 0.80 HDAC4 (0.51) HDAC4HTTSMN1; SMN2CNR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 HDAC4 1442/4885HTT 1708/4885SMN1; SMN2 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.